Open

Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)

Federal funding opportunity RFA-HL-26-019 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes December 23, 2027

Posted: November 22, 2024
Closes: December 23, 2027
Cost sharing: No
Instrument: Grant
Assistance listing: 93.837, 93.233, 93.839, 93.838
Category: Health
Archives: January 28, 2028

Program funding history

Awards made under Assistance Listing 93.837 (one of 4 on this opportunity) across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $3B
FY2026 obligated: $3B
FY2027 (to date) obligated: $0
Awards in window: 10,712

Top recipients: Trustees of the University of Pennsylvania, the, Brigham & Womens Hospital Inc, University of Pittsburgh - of the Commonwealth System of Higher Education, Regents of the University of Michigan, The Leland Stanford Junior University

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

Synopsis

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. This is a phased initiative for early stage projects. The R61 phase provides support to identify and test initial prototype designs, to identify a disease target and generate experimental design, and to identify, test and pilot research tools. The R33 phase provides support for continued prototype development and testing, in addition to modifying design features and user feedback, diagnostic product generation, exploration of assay components, and characterization of a load design, and research tool improvement, large trial testing and data integration. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

Who can apply

City or township governments
County governments
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Private institutions of higher education
Public and State controlled institutions of higher education
Independent school districts
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Special district governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
For profit organizations other than small businesses
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Remind me before this closes

One email about a week before this grant closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
RFA-HL-26-020 · National Institutes of Health · closes December 23, 2027
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
RFA-HL-26-017 · National Institutes of Health · closes December 23, 2027
Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
RFA-HL-26-018 · National Institutes of Health · closes December 23, 2027
Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)
RFA-AI-27-014 · National Institutes of Health · closes October 9, 2028
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
RFA-HL-26-016 · National Institutes of Health · closes December 23, 2027
Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
PA-24-184 · National Institutes of Health · closes May 8, 2027

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing